CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online 2021 December 28 DOI: https://doi.org/10.3350/cmh.2021.0314

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clinical and Molecular Hepatology. 2022;28(2):254-264

Link1

Link2 Link3

The different prognosis of hepatocellular carcinoma with previous tenofovir vs entecavir treatment for chronic hepatitis B virus: analysis based on 15 propensity score–matched studies

Jiancun Hou, Zhe Qiang, Yang Li, Yamin Zhang

Digestive Diseases. 2022;

Link1 Link2

PGI3 Comparative Safety of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in Chronic Hepatitis B Patients

N.Y. Yu, K.C. Chang

Value in Health. 2020;23:S533

Link1 Link2

250 - Renal Outcomes in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Entecavir: A Propensity Score Matched Study

Sam Trinh, An K. Le, Joseph Hoang, Donghak Jeong, Mimi Chung, Mei-Hsuan Lee, Uerica Wang, Mindie H. Nguyen

Gastroenterology. 2018;154(6):S-1081

Link1 Link2

Renal outcomes in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or entecavir: a propensity score matched study

S. Trinh, A. Le, J. Hoang, D. Jeong, M. Chung, M.-H. Lee, U. Wang, M. Nguyen

Journal of Hepatology. 2018;68:S519-S520

Link1 Link2

Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide

Xiaohao Wang, Dachuan Cai, Zhang Juan

Journal of Hepatology. 2022;77:S878

Link1 Link2

P1-086: Effect of vitamin D on treatment response in chronic hepatitis C patients: a propensity score stratification and multilevel analysis

Journal of Viral Hepatitis. 2018;25:66-67

Link1 Link2

Tenofovir disoproxil fumarate is superior to Entecavir and Tenofovir alafenamide in Cost-Effectiveness of Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy

Yi Lin, Xueyan Lin, Juan Chen, Zhihui Lin

. 2023;

Link1 Link2

O-043: Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use

Journal of Viral Hepatitis. 2018;25:27-27

Link1 Link2

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients

Brian T Lee, Mimi Chang, Carolina Lim, Ho S Bae, Tse‐Ling Fong

JGH Open. 2020;5(2):258-263

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.